title: Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?
authors.affiliation: Nutrition Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Y-Y
authors.initials: YY
authors.lastname: Liao
authors.affiliation: Section of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: B-K
authors.initials: BK
authors.lastname: Ahir
authors.affiliation: Nutrition Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: H-Y
authors.initials: HY
authors.lastname: Mo
authors.affiliation: Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: L-Q
authors.initials: LQ
authors.lastname: Li
authors.affiliation: Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. pengningfu@163.com.
authors.forename: N-F
authors.initials: NF
authors.lastname: Peng
mesh_terms: D000998:Antiviral Agents; D006528:Carcinoma, Hepatocellular; D006513:Hepatitis B e Antigens; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic; D006801:Humans; D008113:Liver Neoplasms
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens